KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Intangibles (2016 - 2025)

Sarepta Therapeutics has reported Intangibles over the past 16 years, most recently at $19.0 million for Q4 2025.

  • For Q4 2025, Intangibles fell 29.33% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $19.0 million, down 29.33%, while the annual FY2025 figure was $19.0 million, 29.33% down from the prior year.
  • Intangibles for Q4 2025 was $19.0 million at Sarepta Therapeutics, down from $29.7 million in the prior quarter.
  • Over five years, Intangibles peaked at $30.5 million in Q2 2025 and troughed at $7.2 million in Q1 2023.
  • A 5-year average of $18.8 million and a median of $16.1 million in 2021 define the central range for Intangibles.
  • Biggest five-year swings in Intangibles: crashed 46.78% in 2022 and later soared 301.86% in 2024.
  • Year by year, Intangibles stood at $14.2 million in 2021, then crashed by 46.78% to $7.6 million in 2022, then skyrocketed by 31.96% to $10.0 million in 2023, then surged by 168.87% to $26.9 million in 2024, then fell by 29.33% to $19.0 million in 2025.
  • Business Quant data shows Intangibles for SRPT at $19.0 million in Q4 2025, $29.7 million in Q3 2025, and $30.5 million in Q2 2025.